3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
14
Terminated
2
Withdrawn
1
Unknown
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
16
Myeloid
10
Gastrointestinal
3
Sarcoma
2
Tumor-Agnostic
1
Lymphoid
1
Head & Neck
1
Conditions
Gastrointestinal Stromal Tumors
2
Interventions
Cyclophosphamide
26
Temozolomide
23
Doxorubicin
22
Radiotherapy
21
Filgrastim
19
Ifosfamide
15
pazopanib
14
Gemcitabine
14
Etoposide
13
Bevacizumab
13
Irinotecan
12
Cisplatin
12
Magnetic Resonance Spectroscopy
11
Imatinib Mesylate
11
Granulocyte Colony-Stimulating Factor
11
Carboplatin
11
Radiation
9
Methotrexate
9
pembrolizumab
8
fludarabine phosphate
8
Rituximab
8
Paclitaxel
8
Docetaxel
8
Cyclosporine
8
Busulfan
8
Antilymphocyte Serum
8
fludarabine
7
Vincristine
7
Radiotherapy, Intensity-Modulated
7
Mycophenolic Acid
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
nilotinib
×
Sarcoma
×
Clear all
NCT00751036
2014-03-26
MACS0375
Novartis
Phase 3
Terminated
94 enrolled
10 charts
NCT00782834
2013-04-22
07060
Fox Chase Cancer Center
Phase 2
Terminated
13 enrolled
8 charts